Residency · Residency · Urology

Staghorn Calculi and Struvite Stone Management

Definition and Classification

A staghorn calculus is defined as a kidney stone that occupies the renal pelvis and extends into at least one calyceal group. These calculi are classified as partial or complete staghorn stones. Partial staghorn calculi fill the renal pelvis and one or two calyces, whereas complete staghorn calculi fill the renal pelvis and all calyces, effectively forming a cast of the entire collecting system. The majority of staghorn calculi are composed of struvite, which is magnesium ammonium phosphate, or a mixture of struvite and apatite. However, some staghorn stones are metabolic in origin, consisting of uric acid, cystine, or calcium-based compounds. Determining the stone composition is crucial because management strategies differ depending on the type.

Struvite Stones (Infection Stones)

Pathophysiology

Struvite stones form in the presence of urease-producing bacteria, which hydrolyze urea into ammonia and carbon dioxide. The ammonia then reacts with water to form ammonium hydroxide, which raises the urine pH above 7.2. This alkaline environment leads to supersaturation of magnesium ammonium phosphate and carbonate apatite, promoting stone formation. The most common urease-producing organism is Proteus mirabilis, but other bacteria such as Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus saprophyticus, Providencia, Morganella, and Corynebacterium urealyticum can also produce urease. It is important to note that Escherichia coli does not produce urease and therefore does not directly contribute to struvite stone formation. Risk factors for struvite stones include recurrent urinary tract infections (UTIs), indwelling urinary catheters, neurogenic bladder, urinary diversion, female sex, and anatomic abnormalities that cause urinary stasis.

Clinical Features

Patients with struvite stones may be asymptomatic or present with recurrent UTIs, flank pain, or hematuria. If untreated, these stones can lead to chronic pyelonephritis and progressive renal damage. A persistently alkaline urine pH above 7.2 combined with a positive urine culture for a urease-producing organism is highly suggestive of struvite stone disease. There is also a significant risk of pyonephrosis and sepsis associated with these stones.

<image>CT images of partial and complete staghorn calculi with corresponding plain radiographs showing cast-like filling of the collecting system</image>

Imaging

Non-contrast computed tomography (CT) is the standard imaging modality for staghorn calculi, as it clearly delineates stone burden and renal anatomy, which is essential for operative planning. Kidney-ureter-bladder (KUB) radiographs are useful for monitoring known radiopaque stones and for follow-up after treatment. Imaging assessment should determine whether the staghorn is complete or partial, evaluate calyceal anatomy and infundibular dimensions, assess the function of the contralateral kidney, and examine surrounding structures to plan percutaneous nephrolithotomy (PCNL) access.

Principles of Management

The primary goal in managing staghorn calculi is complete stone clearance because residual fragments act as a nidus for recurrent stone formation and persistent infection. Untreated staghorn stones carry significant morbidity, including progressive renal deterioration and recurrent sepsis. Historical series have reported a 28% mortality rate at 10 years with observation alone. Therefore, even asymptomatic staghorn calculi should be treated, as recommended by the American Urological Association (AUA) guidelines.

Surgical Management

PCNL (Primary Treatment)

Percutaneous nephrolithotomy is the first-line treatment for staghorn calculi. It often requires multiple access tracts or staged procedures to achieve complete clearance. Planning involves identifying the optimal primary access, usually through the posterior lower-pole calyx, and establishing secondary access tracts to reach branching extensions in the upper pole or anterior calyces. Maximizing stone clearance during each session reduces the need for multiple procedures. Stone-free rates with PCNL monotherapy range from 56% to 78% in a single session and can reach up to 90% with staged or combined approaches.

Combination Therapy

Combination therapies include PCNL with ureteroscopy (URS), often referred to as "sandwich therapy," where PCNL is used for bulk stone removal and flexible URS targets residual fragments in difficult-to-reach calyces. PCNL combined with shock wave lithotripsy (SWL) is another option, although its use is declining in favor of URS for residual fragments. Second-look PCNL involves flexible nephroscopy through the existing tract 48 to 72 hours after the initial procedure to remove any remaining fragments.

Anatrophic Nephrolithotomy

Anatrophic nephrolithotomy is an open surgical technique involving controlled renal hypothermia and a nephrotomy along Brodel's avascular plane. Historically considered the gold standard for complete staghorn clearance, it is now reserved for cases with complex anatomy not amenable to percutaneous approaches, concurrent need for infundibuloplasty or calyceal repair, or failed percutaneous procedures. This approach achieves excellent stone-free rates of approximately 90-100% but carries higher morbidity compared to PCNL.

Nephrectomy

Nephrectomy is indicated when the affected kidney is non-functioning, typically defined as less than 10-15% differential function on renal scan, or in cases of recurrent sepsis from the stone-bearing kidney. It is also the treatment of choice for xanthogranulomatous pyelonephritis (XGP), a chronic inflammatory condition associated with staghorn calculi.

<image>Operative planning diagram for staghorn calculus showing primary lower-pole access tract and secondary upper-pole access for complete clearance</image>

Perioperative Infection Management

Preoperative urine cultures and targeted antibiotic therapy are essential. However, bladder urine cultures may not accurately reflect the microbial flora of the renal pelvis or stone, as stone cultures often differ. Broad-spectrum antibiotics covering gram-negative organisms, including Pseudomonas, should be administered perioperatively. During PCNL, intrarenal pressure must be carefully managed by minimizing irrigation pressure and maintaining low intrarenal pressure, often achieved by using an Amplatz sheath for passive drainage. Elevated intrarenal pressure increases the risk of bacteremia and sepsis. Postoperative culture of stone fragments is critical to guide further antibiotic therapy.

Struvite-Specific Medical Therapy

Acetohydroxamic Acid (AHA)

Acetohydroxamic acid is a urease inhibitor that blocks the production of ammonia from urea. It is indicated as an adjunctive therapy when complete stone clearance is not achievable or to prevent recurrence. The typical dosing is 250 mg three times daily, with a maximum of 1.5 grams per day. AHA reduces stone growth and recurrence by approximately 50%. However, its use is limited by significant side effects, including headache in 30% of patients, tremor, phlebitis, deep venous thrombosis (6-7%), hemolytic anemia (Coombs-positive), gastrointestinal disturbances, and teratogenicity, making it contraindicated in pregnancy. Therefore, AHA is reserved for patients with persistent urease-producing infections and incomplete stone clearance.

Long-Term Antibiotic Suppression

Long-term suppressive antibiotic therapy, guided by culture results, is used to prevent recurrence, especially in patients with anatomic risk factors such as neurogenic bladder or urinary diversion. While this approach does not eliminate stones, it reduces the rate of stone growth.

Acidification

Although urine acidification is theoretically beneficial in preventing struvite stone formation, it is difficult to achieve in practice due to the persistent urease-producing infection and is not considered a primary treatment strategy.

<image>Intraoperative nephroscopic view during PCNL for staghorn calculus showing bulk stone removal with ultrasonic lithotripter</image>

Recurrence Prevention

Complete stone clearance remains the single most important factor in preventing recurrence. Post-treatment protocols include stone analysis to confirm struvite versus metabolic composition, stone culture with directed antibiotic therapy, imaging at three months post-treatment and then every six to twelve months, and urine cultures every three to six months. A 24-hour urine collection is indicated if a metabolic component is suspected. Modifiable risk factors such as indwelling catheters should be removed or changed, anatomic abnormalities like strictures or reflux should be treated, and bladder management optimized in neurogenic patients. Acetohydroxamic acid may be considered if recurrence occurs despite these measures.

Xanthogranulomatous Pyelonephritis (XGP)

XGP is a chronic inflammatory condition often associated with staghorn calculi and urinary obstruction. Pathologically, it is characterized by lipid-laden macrophages replacing the renal parenchyma. On imaging, XGP can mimic renal malignancy, and diagnosis is usually made postoperatively on histopathology. Treatment typically involves nephrectomy, which can be challenging due to perinephric inflammation and adhesions.

Clinical Pearls

The cornerstone of treatment for struvite and staghorn calculi is complete stone clearance, as residual fragments will inevitably regrow if infection persists. Bladder urine cultures do not reliably predict the microbial flora of the stone or renal pelvis; therefore, stone fragments should always be sent for culture. Since E. coli does not produce urease, its presence in a patient with stones does not explain struvite formation, and other urease-producing organisms should be sought. In cases where staghorn calculi are present in a non-functioning kidney, nephrectomy is preferred over complex stone surgery. During PCNL, minimizing intrarenal pressure is critical to reducing the risk of sepsis, and the Amplatz sheath plays a vital role in providing passive drainage. Acetohydroxamic acid is the only FDA-approved drug for infection stone prevention, but its significant side-effect profile, particularly the risk of deep venous thrombosis, limits its widespread use. Finally, even asymptomatic staghorn calculi warrant treatment, as observation alone carries a 28% mortality rate at 10 years.

References

• AUA Guideline on Staghorn Calculi, 2005 (reaffirmed)
• EAU Guidelines on Urolithiasis, 2024 Update
• Aron M, et al. "Staghorn calculi: what has changed?" Urol Clin North Am. 2007;34(3):441-454.
• Griffith DP, et al. "Acetohydroxamic acid: clinical studies of a urease inhibitor." J Urol. 1978;119(1):9-15.
• Flannigan R, et al. "Renal struvite stones -- pathogenesis, microbiology, and management strategies." Nat Rev Urol. 2014;11(6):333-341.
• Campbell-Walsh-Wein Urology, 12th Edition, Chapter on Staghorn Calculi

Read this lecture as Markdown